New PET tracers aim to spot tau tangles in rare brain disease
NCT ID NCT07348276
First seen Jan 17, 2026 · Last updated Jun 22, 2026 · Updated 18 times
Summary
This early-phase study tests two new imaging drugs, [18F]ABBV-964i and [18F]ABBV-965i, designed to light up tau protein buildup in the brain during a PET scan. Tau buildup is linked to Progressive Supranuclear Palsy (PSP), a rare movement and thinking disorder. The trial includes up to 24 adults (healthy volunteers and people with PSP) to check safety, radiation exposure, and how well the drugs show tau in the brain. Better imaging could help diagnose PSP earlier and track disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Invicro (dba Perceptive)
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]ABBV-964i and [18F]ABBV-965i (imaging drugs used in PET scans)
What this could lead to
If successful, these imaging drugs could help doctors see tau buildup in the brain, leading to earlier and more accurate diagnosis of PSP and better tools for tracking the disease.
What could go wrong
This is a very early, small study (24 people) focused on safety and imaging quality, not treatment. The drugs may not work as hoped, and results may not apply to larger groups.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.